A retrospective surgical cohort found less delirium with remimazolam, but statistical target-trial methods did not make drug assignment randomized.
What the source reports
The study included 1,123 surgical patients with hyperlipidemia. Delirium within three days occurred in 13.8% of remimazolam recipients versus approximately 21% of others. The target-trial analysis estimated an adjusted risk difference of about minus 5.3 percentage points. Severity and later cognitive outcomes also favored the exposed group.
Limits and uncertainty
Unmeasured differences in treatment choice and clinical condition can remain after adjustment. Dose-response cut points were derived from these data and require prospective validation. The proposed inflammatory explanation was not independently established by the clinical association, and the results should not be generalized to all benzodiazepines.
Implications for forensic review
For an expert report, describe the design before using causal language. A modeled threshold is not a proven protective dose or a reason to infer benefit in a specific patient. Assess baseline lipids, operation, co-treatment and the delirium assessment schedule before comparing an individual course with the cohort.
Source and related reading
Source reviewed: Remimazolam and Postoperative Delirium in Patients with Hyperlipidemia A Retrospective Cohort Study (PMC13005258). Forensic applications above are interpretive analysis of the supplied paper.
Related reading: Dominant Midazolam Sedation Was Associated With ICU Delirium in a Matched Cohort.
Leave a Reply